Clinical trials: Macular Degeneration Choroidal Neovascularization
Choroidal Neovascularization
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
The purpose of study is to determine if Lucentis combined with imatinib mesylate will help treatment in patients with newly diagnosed choroidal neovascularization.
- Trial name
- NCT00403156
- Testing
- Imatinib Mesylate /Ranibizumab
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Polypoidal Choroidal Vasculopathy
Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
This Phase I/II study will investigate the safety and tolerability of intravitreally administered 0.5mg and 1.0 or 2.0mg Ranibizumab in three monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and…
- Trial name
- NCT01469156
- Testing
- ranibizumab 0.5 or 2.0 mg/0.05 cc
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Macular Degeneration, Choroidal Neovascularization
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
Evaluation of Dosing Interval of Higher Doses of Ranibizumab for patients with wet age-related macular degeneration (AMD).
- Trial name
- BGB/IST (NCT00533520)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Brandon G. Busbee, MD
Uveitis, Diabetic Retinopathy
Biomarkers of Common Eye Diseases
To identify biomarkers of common eye diseases based on single-cell sequencing technologies using PBMC samples. These diseases include uveitis, diabetic retinopathy, age-related macular degeneration and polypoid choroidal…
- Conditions
- Uveitis, Diabetic Retinopathy, Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
- Trial name
- NCT04101604
- Testing
- Collection of blood samples
- Where
- China
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Ocular Histoplasmosis Syndrome
Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome
The purpose of this study is to evaluate the safety and effectiveness of intravitreal ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular histoplasmosis.
- Trial name
- IVL for OHS (NCT00955630)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Retina Associates of Kentucky
Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers, Choroidal Neovascularization
Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops
Study of the safety, tolerability and pharmacokinetic profile of different doses of SYL1801 eye drops in healthy volunteers.
- Trial name
- NCT04782271
- Testing
- SYL18001 sodium Low dose q.d, SYL18001 sodium Middle dose q.d, SYL18001 sodium High dose q.d
- Where
- Spain
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sylentis, S.A.
Myopic Choroidal Neovascularization
Ranibizumab for Myopic Neovascularization
The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).
- Trial name
- NCT01246089
- Testing
- ranibizumab injection
- Where
- Brazil
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Instituto de Olhos de Goiania
Retinal Diseases, Choroidal Disease
An Interpretable Fundus Diseases Report Generating System Based On Weakly Labelings
To establish a multimodal fundus image report generation model to realize an interpretable system for multiple fundus diseases, multimodal image analysis, diagnosis, and treatment decision automatic reporting based on weakly…
- Conditions
- Retinal Diseases, Choroidal Disease, Pathological Myopia, Diabetic Retinopathy
- Trial name
- NCT06918028
- Testing
- With fundus diseases, Without fundus diseases
- Where
- China
- Volunteers
- 9,999 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Exudative Age-Related Macular Degeneration
Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degeneration (ARMD)
The purpose of this study is to evaluate the fact that 20 milligrams per day of oral Zeaxanthin as a supplement to patients with Choroidal neovascularization (CNV) and exudative age related macular degeneration (ARMD) undergoing…
- Trial name
- ARMD (NCT01527435)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The Retina Center of St. Louis County, PC
Polypoidal Choroidal Vasculopathy
Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)
This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.
- Trial name
- PEARL (NCT00424710)
- Testing
- ranibizumab intravitreal injection
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Hawaii Pacific Health
Wet Macular Degeneration
Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy
The purpose of this study is to evaluate the effects and safety of ranibizumab therapy combined with TA versus ranibizumab monotherapy in patients with polypoidal choroidal vasculopathy (PCV).
- Trial name
- RANTA (NCT02806752)
- Testing
- Triamcinolone Acetonide, Ranibizumab
- Where
- 7 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Aier School of Ophthalmology, Central South University
Macular Degeneration, Age-related Macular Degeneration
A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.
This is a two-part study to evaluate the safety, tolerability and pharmacokinetics of single (Part A) and repeat (Part B) eye drop doses of pazopanib in healthy adult and elderly subjects.
- Trial name
- NCT00463320
- Testing
- Pazopanib eye drops and Allergen Refresh Plus eye drops
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Age Related Macular Degeneration
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
This is an open label study to evaluate 2.0 mg intravitreal aflibercept injection administered in subject who have active choroidal neovascularization due to Age Related Macular Degeneration (AMD).
- Trial name
- NCT01657669
- Testing
- Intravitreal Aflibercept injection
- Where
- 3 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Retina Research Institute, LLC
Choroidal Neovascularization
Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy
The primary objective: *To measure the difference in the number of Ranibizumab therapies needed in 12 months in the Posterior Vitreous Detachment (PVD) positive and Posterior Vitreous Detachment (PVD) negative group.
- Trial name
- PVD (NCT01256632)
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vision Research Foundation
Polypoidal Choroidal Vasculopathy
Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
Monthly, continuous anti-vegf therapy for patients presenting with active polypoidal choroidal vasculopathy. Two arms, treatment naive and previously treated with an FDA approved anti-VEGF therapy, will be randomized and dosed…
- Trial name
- PEARL2 (NCT01248117)
- Testing
- ranibizumab 2.0mg
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Retina Consultants of Hawaii
Myopic Choroidal Neovascularisation
OCTA Changes in Choroidal Neovascularization in High Myopia
To Analyze the Ability of Optical Coherence Tomography Angiography ( OCT-A ) to detect the presence of myopic Choroidal Neovascularization and to describe the structural features of Myopic CNV..
- Trial name
- NCT06357559
- Testing
- OCTA
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sohag University
Subfoveal Choroidal Neovascularization
Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization
The purpose of this study is to compare the efficacy of photodynamic therapy with verteporfin (PDT) and IVTA vs triple therapy (TT) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular…
- Trial name
- NCT00930189
- Testing
- intravitreal injection of ranibizumab, intravitreal injection of triamcinolone, photodynamic therapy
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- Asociación para Evitar la Ceguera en México
Polypoidal Choroidal Vasculopathy
Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
This Phase I/II safety study is designed to investigate the safety and efficacy of ranibizumab (Lucentis) in the treatment of polypoidal choroidal vasculopathy (PCV), a potentially blinding eye disease that involves the growth of…
- Trial name
- NCT00837330
- Testing
- ranibizumab 0.5 or 0.3 mg/0.05 cc
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Macular Degeneration Choroidal Neovascularization
Deep Learning Optical Coherence Tomography (OCT) and OCT Angiography (OCTA) in NVC
To evaluate the activity of neovascular macula degeneretion as assessed by SD-OCTand OCT-A using a split-person study design and deep-learning quantification.
- Trial name
- OCTA (NCT05969418)
- Testing
- Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter
- Where
- Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Federico II University
Ocular Histoplasmosis
Treatment for Presumed Ocular Histoplasmosis
The purpose of this study is to monitor safety outcomes for patients being treated with intravitreal aflibercept injections for choroidal neovascularization secondary to Presumed Ocular Histoplasmosis Syndrome.
- Trial name
- HANDLE (NCT01790893)
- Testing
- aflibercept
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- John Kitchens, MD